FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (41)AstraZeneca licenses novel EGFR inhibitor
Preheader (134)AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
Arial
Text Analysis
Body Words132
Subject Words5
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px752 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekWednesday
TimeEvening
